[1] Rockey DC, Bell PD, Hill JA. Fibrosis -a common pathway to organ injury and failure. N Engl J Med,2015,372:1138-1149.
[2] M?ller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int,2018,38:570-580.
[3] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the Management of Patients with Decompensated Cirrhosis. J Hepatol,2018,69:406-460.
[4] Clària J, Stauber RE, Coenraad MJ, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology,2016,64:1249-1264.
[5] Trebicka J,Fernandez J, Papp M,et al.The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol, 2020, 73:842-854.
[6] Macdonald S, Andreola F, Bachtiger P, et al. Cell death markers in patients with cirrhosis and acute decompensation. Hepatology,2018,67:989-1002.
[7] Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature,2015,517:311-320.
[8] Bernsmeier C, Pop OT, Singanayagam A, et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase Mertk. Gastroenterology,2015,148:603-615.
[9] Bernsmeier C, Triantafyllou E, Brenig R, et al. CD14+ CD15- HLA-DR- myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure. Gut, 2018,67:1155-1167.
[10] Korf H, du Plessis J, van Pelt J, et al. Inhibition of glutamine synthetase in monocytes from patients with acute-on-chronic liver failure resuscitates their antibacterial and inflammatory capacity. Gut,2019,68:1872-1883.
[11] Mookerjee RP, Stadlbauer V, Lidder S, et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology 2007;46:831-40.
[12] Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med,2013,369:840-851.
[13] Ganeshan K, Nikkanen J, Man K, et al. Energetic trade-offs and hypometabolic states promote disease tolerance. Cell,2019,177:399-413.
[14] Moreau R, Clària J, Aguilar F, et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. J Hepatol, 2020, 72(4):688-701..
[15] Chaudhury C, Mehnaz S, Robinson JM, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med,2003,197:315-322.
[16] Fernández J, Clària J, Amorós A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology,2019,157:149-162.
[17] Arroyo V, García-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol,2014,61:396-407.
[18] Fernández J, Monteagudo J, Bargallo X, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology,2005,42:627-634.
[19] Ortega R, Ginès P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology, 2002,36:941-948.
[20] Quon CY. Clinical pharmacokinetics and pharmacodynamics of colloidal plasma volume expanders. J Cardiothorac Anesth,1988,2:13-23.
[21] Domenicali M, Baldassarre M, Giannone FA, et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology, 2014,60:1851-1860.
[22] Alcaraz-Quiles J, Casulleras M, Oettl K, et al. Oxidized albumin triggers a cytokine storm in leukocytes through p38 mitogen-activated protein kinase: role in systemic inflammation in decompensated cirrhosis. Hepatology,2018,68:1937-1952.
[23] Jalan R, Bernardi M. Effective albumin concentration and cirrhosis mortality: from concept to reality. J Hepatol,2013,59:918-920.
[24] Caraceni P, Riggio O, Angeli P, et al. Long-Term albumin administration in decompensated cirrhosis (answer): an open-label randomised trial. Lancet,2018,391:2417-2429.
[25] Di Pascoli M, Fasolato S, Piano S, et al. Long-Term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver Int,2019,39:98-105.
[26] Solà E, Solé C, Simón-Talero M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol,2018,69:1250-1259.
[27] Garcia-Martinez R, Andreola F, Mehta G, et al. Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure. J Hepatol,2015,62:799-806.
[28] Oettl K, Marsche G. Redox state of human serum albumin in terms of cysteine-34 in health and disease. Methods Enzymol,2010,474:181-195. |
